Abstract 433P
Background
An estimated 70-80% of malignancies need multimodal treatment, which includes surgery, radiation, and chemotherapy. Radiation oncology is particularly vulnerable to regional disparities in access to care due to the unique nature of its treatments.It is vital to define geographic and demographic access to radiotherapy in order to improve patient access to clinical care.This first of its kind study aimed at quantifying the available radiation oncology resources across all Asian counties.
Methods
The availability of Teletherapy and Brachytherapy resources of all Asian Countries was obtained from IAEA-DIRAC. The population o was estimated using World Bank Population Estimates. The incidence of cancers was obtained from Globocan Reports.Available number of treatment units were compared with that of the population, overall cancer incidence and five most common cancers among countries across Asia. Total EBRT treatment capacity was estimated by multiplying the number of units per country with 240 working days. Assuming that 50 patients would be treated per day, a proportional treatment space of 15% was estimated for Breast and lung cancers and, 10% each for stomach, cervical and oesophageal cancers. Therefore, feasible fractions were estimated as: number of EBRT units per country × 240 × (0.15 or 0.10) × 50. Number of excess or deficit fractions were calculated, and the total number of extra machines required was arrived at.
Results
Number of teletherapy units varied from 1 to 1825 across countries. Yemen had the least number of teletherapy units per million population (0.03) whereas Japan had the highest (8.66). Brunei had 1 teletherapy machine per 493 cancer cases whereas North Korea had 1 machine per 19218 cases. Qatar had 1 brachytherapy machine for 1482 cancer cases and Taiwan had 1 Brachytherapy machine for 55483 cancer cases.41 countries had a deficit in number of teletherapy machines with respect to breast cancer. Similarly, 33, 28, 32 and 18 countries had a deficit with respect to lung, stomach, cervical and oesophageal cancers respectively.
Conclusions
The study identified deficits of radiotherapy units in terms of geographic and demographic aspect across Asian countries and provides a roadmap for development of radiation oncology infrastructure.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Abhishek Krishna.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
409P - Tertiary lymphoid structures are scarce but associated with BCR clonal expansion, B cell activity and checkpoint inhibitor response in advanced osteosarcoma
Presenter: Qiyuan Bao
Session: Poster viewing 06
410P - The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
Presenter: Thanawat Suksomboon
Session: Poster viewing 06
411P - Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022
Presenter: Suresh Attili
Session: Poster viewing 06
412P - Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population
Presenter: Fang Gao
Session: Poster viewing 06
413P - Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database
Presenter: Soojung Hong
Session: Poster viewing 06
414P - Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting
Presenter: Ghazal Tansir
Session: Poster viewing 06
415P - Small cell lung cancer: Epidemiological patterns and mutational profile in the United States
Presenter: Abdallah Allam
Session: Poster viewing 06
416P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: Poster viewing 06
417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study
Presenter: Xudong Sun
Session: Poster viewing 06
418P - Mutational landscape of non-small cell lung cancer in the United States
Presenter: Mostafa Elsayed
Session: Poster viewing 06